Skip to main content
IPSEY logo

Ipsen S.A. (IPSEY) Stock Price & Analysis

Ipsen S.A. (IPSEY) — price $45.12 (-3.61%), as of the Nov 19, 2026 trading session; market cap $14.9B.

Educational signal · not a buy or sell recommendation · How to read this

$45.12 −$1.69 (-3.61%) Market Cap $14.9B

Ipsen S.A. · IPSEY · Healthcare · Drug Manufacturers - Specialty & Generic

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide.

Price as of Nov 19, 2026

Key Statistics

Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • ELAN · Elanco Animal Health Incorporated · 35 /100
  • RDY · Dr. Reddy's Laboratories Limited · 77 /100
  • VTRS · Viatris Inc. · 35 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$45.12
Change on the day-3.61%
52-week range$34.34–$51.10
Market capitalisation$14.9B—
Price / earnings (trailing)26.47
Shares traded on the day1
Beta (volatility vs the S&P 500)0.32

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $33, high $49, latest $45. $49 $33 high $49 Oct 17, 2025 Nov 19, 2026 · $45 $33Oct 17, 2025$35Oct 31, 2025$38Nov 14, 2025$37Nov 28, 2025$36Dec 12, 2025$35Dec 26, 2025$37Jan 9, 2026$41Jan 23, 2026$40Feb 6, 2026$46Feb 20, 2026$46Mar 6, 2026$45Mar 20, 2026$49Apr 2, 2026$49Apr 17, 2026$49May 1, 2026$49May 15, 2026$45May 29, 2026$47Jun 12, 2026$47Jun 26, 2026$48Jul 10, 2026$45Jul 24, 2026$46Aug 7, 2026$48Aug 21, 2026$49Sep 4, 2026$45Sep 18, 2026$42Oct 2, 2026$41Oct 16, 2026$44Oct 30, 2026$47Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Ipsen (IPSEY): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

6 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Neutral read
Simons-style lens (simulated) Jim Simons Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Favorable read
Moon AI lens (model) Favorable read

Read on: Nov 16, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Neutral
Margin of Safety Fairly Valued
Profit Margin Neutral
Revenue Growth Negative
Debt/Equity Moderate
ROE Neutral
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Ipsen (IPSEY), and what does it report?

Short answer

Ipsen S.A., a biopharmaceutical company, develops and commercializes medicines in the areas of oncology, rare disease, and neuroscience worldwide. Healthcare / Drug Manufacturers Specialty & Generic Headquarters: 70 rue Balard, Paris, IF, 75015, FR. It employs 5,535 people and is led by David G. Loew. In Q2 FY2026 it reported revenue of €2.30B and net income of €403M. The market values it at $14.9B.

2 · Latest results

What do the latest results show for Ipsen (IPSEY)?

Short answer · as of

The most recent reported quarter, Q2 FY2026, carried revenue of €2.30B. Against analyst estimates the company has EPS beat 7 of the last 8 reports.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q2 FY2026€2.30B€403M€1.22 (diluted)
Q4 FY2025€1.84B€109M€0.28 (diluted)
Q2 FY2025€1.94B€334M€1.00 (diluted)
Q4 FY2024€1.82B€114M€0.34 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Ipsen (IPSEY)?

Short answer · as of

The distress and quality screens read Altman Z 13.67 · Piotroski F 6. Trailing ratios: ROE 11.3% · ROA 6.9% · current ratio 1.97 · earnings yield 3.7% · free-cash-flow yield 8.9%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held IPSEY in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported IPSEY in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Ipsen (IPSEY)?

Read these with our analysis →

IPSEY Healthcare Stock FAQ

These answers are editorial: 1 of these 8 answers is drawn from the IPSEY research dossier (written Mar 15, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is IPSEY a good stock to buy?

Stock Expert AI does not rate IPSEY buy, sell or hold. Ipsen S.A. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the IPSEY stock price today?

The last price recorded for Ipsen S.A. (IPSEY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for IPSEY?

The main risks for Ipsen S.A. include increasing competition from generic drug manufacturers, which could erode sales of its established products. The uncertainty of clinical trial outcomes poses a risk to its pipeline of new therapies.

What are the key factors to evaluate for IPSEY?

Evaluate IPSEY on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Strategic acquisitions to expand product portfolio: Ipsen can pursue strategic acquisitions to expand its product portfolio and gain access to new therapeutic areas or technologies. Not financial advice.

How frequently does IPSEY data refresh on this page?

IPSEY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven IPSEY's recent stock price performance?

Ipsen S.A. (IPSEY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product portfolio in specialty care. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider IPSEY overvalued or undervalued right now?

The trailing P/E of Ipsen S.A. (IPSEY) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research IPSEY before investing?

Before investing in Ipsen S.A. (IPSEY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 19 figures on this page — 15 from Financial Modeling Prep (FMP) and 4 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.